IMMX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
15.9M
+28.0%
12.5M
+15.3%
10.8M
-0.8%
10.9M
+42.2%
7.7M
R&D
5.5M
+3.9%
5.3M
-10.8%
6.0M
+4.4%
5.7M
+24.9%
4.6M
SG&A
10.4M
+46.1%
7.1M
+47.7%
4.8M
-6.6%
5.2M
+67.8%
3.1M
Operating Income
-15945871
-28.0%
-12456343
-15.3%
-10803855
+0.8%
-10893276
-42.2%
-7662509
EBITDA
-15851579
-28.2%
-12365350
-15.4%
-10712278
+1.2%
-10841162
-43.3%
-7565523
Net Income
-13927180
-20.5%
-11557002
-14.6%
-10086687
+5.6%
-10687830
-40.9%
-7585692
EPS (Basic)
$-0.19
-5.6%
$-0.18
+0.0%
$-0.18
+33.3%
$-0.27
-12.5%
$-0.24
EPS (Diluted)
$-0.19
-5.6%
$-0.18
+0.0%
$-0.18
+33.3%
$-0.27
-12.5%
$-0.24
Shares (Diluted)
74.1M
+16.2%
63.8M
+15.2%
55.4M
+37.6%
40.3M
+26.1%
31.9M
Immix Biopharma (IMMX) — Financials